All News

With a low number of approved medications for pediatric plaque psoriasis, secukinumab is a valuable new addition to the limited treatment options available.

Megan Olsen, MPH, principal at Avalere, discusses how the impact of small patient populations and other limitations may influence payer conversations about gene and cell therapies.

Researchers recommend vaccination against COVID-19 for patients with multiple sclerosis (MS) after confirming that several types of vaccines are safe and produced no significant adverse events.

An abstract presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition shows that although daratumumab use in multiple myeloma holds great promise, challenges remain in the use of clinical pathways for treatment direction with the monoclonal antibody—which the investigators say may also present opportunities for change.

Women with systemic lupus erythematosus (SLE) were twice as likely to experience carotid plaque buildup during the 5 years of this study.

Next Gen ACO recently re-branded as the Value Based Care Coalition. To learn more about the organization's new phase, we spoke with executive director Mara McDermott.

In a new review article, investigators outline the challenges to studying the disease, but also point to big data as an important tool moving forward.

John Burke, MD, hematologist, Rocky Mountain Cancer Centers, discussed findings of the late-breaking abstract session POLARIX presented at ASH 2021, which compared pola-R-CHP with standard-of-care R-CHOP in patients with previously untreated DLBCL.

More Americans reported skipping medical care over cost concerns; today marks the 1-year anniversary of the COVID-19 vaccine rollout; hospitals in Minnesota are overwhelmed with COVID-19 patients.

Results presented at the 63rd Annual American Society of Hematology Meeting showed that using polatuzumab vedotin instead of vincristine in R-CHOP improved progression-free survival in patients with newly diagnosed diffuse large B-cell lymphoma.

David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine, outlines potential mechanisms underlying menstrual-related migraine.

Recent surveys shed light on oncologist and patient perceptions of the switch to biosimilars and patient mental health.

Frederick Locke, MD, vice chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy Program, co-leader, Immuno-Oncology, Moffitt Cancer Center, discusses findings of the phase 3 ZUMA-7 trial presented at ASH 2021 and how use of axicabtagene ciloleucel can be optimally applied in a real-world setting.

Patients who have experienced acute kidney injury (AKI) reported experiencing significant impacts on aspects of their physical and emotional health, demonstrating the different ways that AKI episodes influence patients’ health-related quality of life.

Sattva S. Neelapu, MD, professor and deputy department chair in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses findings of the ZUMA-12 study examining axicabtagene ciloleucel (axi-cel) as a first-line treatment option for high-risk patients with large B-cell lymphoma.

Leon Herndon Jr, MD, a glaucoma specialist, ophthalmologist, and professor of ophthalmology at the Duke University Eye Center, explains certain considerations ophthalmologists may need to take into account when treating older patients and the need for more specialists to meet clinical demand.

Two-third of those who receive a chronic lymphocytic leukemia (CLL) diagnosis are age 65 or older, so the ease with which drugs are covered in Medicare has an outsized role in patient access to care.

Two posters presented at The Liver Meeting identified the primary care coordinators for patients with nonalcoholic steatohepatitis (NASH) and areas of unmet need among specialists to provide optimal management.

Mark Wildgust, PhD, vice president, Global Medical Affairs, Oncology, Janssen, speaks on progression-free survival, complete response, and overall survival benefits observed with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 and other studies presented at the 63rd Annual American Society of Hematology Meeting and Exposition.

Two doses of the Pfizer vaccine may only have 22.5% efficacy against the Omicron variant; as of 2018, less than 16% of orthopedic specialists are people of color; a mask mandate for stores and indoor spaces in New York state went into effect.

Next-generation sequencing (NGS) may be a helpful tool for establishing how B cells migrate and maturate across the blood-brain barrier in multiple sclerosis (MS), potentially providing better insight into the pathophysiologic mechanisms involved in neuro-inflammation.

The researchers said they believe it is the first study to show the presence of hepatic fibrosis in patients with chronic right heart failure accompanied by pulmonary arterial hypertension (PAH) using liver ultrasound elastography.

Frederick L. Locke, MD, of Moffitt Cancer Center in Tampa, Florida, is the lead study author of the phase 3 ZUMA-7 trial, which examined the use of axi-cel in second-line treatment of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL).

Lori Muffly, MD, associate professor of medicine, Blood & Marrow Transplantation, Stanford University, discusses findings of her study showing disparities in clinical trial enrollment and patient outcomes for at-risk pediatric minority populations with acute lymphoblastic leukemia (ALL).

Zanubrutinib produced prolonged progression-free survival (PFS) compared with a combination of bendamustine and rituximab among treatment-naïve patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL).

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center, speaks on molecular features of diffuse large B-cell lymphoma and how this explains differences in patient response for chemotherapy and chimeric antigen receptor (CAR) T-cell therapy.

Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, discusses the superior safety and progression-free survival outcomes from the SEQUOIA phase 3 trial, which compared zanubrutinib with bendamustine and rituximab combination therapy in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma.

Chronic cough can be very debilitating to a patient's quality of life, explained Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

Investigators discuss the humoral response to enzyme-replacement therapy in their review of the clinical picture and diagnostic confirmation of Fabry disease.

In a recent case report, researchers outlined the case of a patients with shellfish allergy–induced overlap chronic graft versus host disease (ocGVHD)—a case of GVHD that has components of both acute and chronic GVHD.